The estimated Net Worth of Alison L. Hannah is at least $818 Tausend dollars as of 10 August 2024. Dr Hannah owns over 11,336 units of CytomX Therapeutics Inc stock worth over $155,587 and over the last 9 years he sold CTMX stock worth over $7,955. In addition, he makes $654,563 as Sr. VP & Chief Medical Officer at CytomX Therapeutics Inc.
Sign up
Dr D CTMX stock SEC Form 4 insiders trading
Dr has made over 9 trades of the CytomX Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 11,336 units of CTMX stock worth $14,850 on 10 August 2024.
The largest trade he's ever made was buying 20,000 units of CytomX Therapeutics Inc stock on 27 July 2017 worth over $183,800. On average, Dr trades about 3,303 units every 110 days since 2015. As of 10 August 2024 he still owns at least 118,769 units of CytomX Therapeutics Inc stock.
You can see the complete history of Dr Hannah stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Alison L. Hannah M.D. biography
Dr. Alison L. Hannah M.D. is the Sr. VP & Chief Medical Officer at CytomX Therapeutics Inc.
What is the salary of Dr D?
As the Sr. VP & Chief Medical Officer of CytomX Therapeutics Inc, the total compensation of Dr D at CytomX Therapeutics Inc is $654,563. There are 6 executives at CytomX Therapeutics Inc getting paid more, with Sean McCarthy having the highest compensation of $3,769,930.
How old is Dr D?
Dr D is 60, he's been the Sr. VP & Chief Medical Officer of CytomX Therapeutics Inc since . There are 7 older and 11 younger executives at CytomX Therapeutics Inc. The oldest executive at CytomX Therapeutics Inc is Frederick W. Gluck, 86, who is the Co-Founder & Independent Director.
What's Dr D's mailing address?
Alison's mailing address filed with the SEC is 9490 NEOGENOMICS WAY, , FORT MYERS, FL, 33912.
Insiders trading at CytomX Therapeutics Inc
Over the last 9 years, insiders at CytomX Therapeutics Inc have traded over $57,157,858 worth of CytomX Therapeutics Inc stock and bought 662,000 units worth $7,876,720 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Harbor Master Investors (Ca... und James E Deerfield Mgmt L.P..... On average, CytomX Therapeutics Inc executives and independent directors trade stock every 20 days with the average trade being worth of $48,707. The most recent stock trade was executed by Jeffrey B Landau on 20 August 2024, trading 11,250 units of CTMX stock currently worth $14,738.
What does CytomX Therapeutics Inc do?
cytomx is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its probody technology platform. the company uses the platform to create development-stage proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. cytomx believes that its probody platform has the potential to improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and t-cell-recruiting bispecific antibodies. probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. investigational probody therapeutics are being developed that address clinically-validated cancer targets in immuno-oncology, such as pd-l1 against which o
What does CytomX Therapeutics Inc's logo look like?
Complete history of Dr Hannah stock trades at CytomX Therapeutics Inc, Neogenomics und Rigel Pharmaceuticals
CytomX Therapeutics Inc executives and stock owners
CytomX Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Sean McCarthy,
Chairman of the Board, President, Chief Executive Officer -
Amy Peterson,
Executive Vice President, Chief Development Officer -
W. Michael Kavanaugh,
Senior Vice President, Chief Scientific Officer and Head - Research and Non-Clinical Development -
Lloyd Rowland,
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary -
Dr. Sean A. McCarthy D.Phil., DPHIL,
Chairman & CEO -
Dr. Amy C. Peterson M.D.,
Pres & COO -
Dr. Alison L. Hannah M.D.,
Sr. VP & Chief Medical Officer -
Lloyd A. Rowland Jr., J.D.,
Sr. VP, Gen. Counsel, Chief Compliance Officer & Sec. -
Elaine Jones,
Independent Director -
Matthew Young,
Lead Independent Director -
John Scarlett,
Independent Director -
Frederick Gluck,
Independent Director -
James Meyers,
Independent Director -
Charles Fuchs,
Independent Director -
Frederick W. Gluck,
Co-Founder & Independent Director -
Alison Hannah,
Senior Vice President, Chief Medical Officer -
Halley Gilbert,
Independent Director -
Carlos Campoy,
Chief Financial Officer, Senior Vice President -
Christopher Keenan,
Vice President, Investor Relations and Corporate Communications -
Nick Galli,
Senior Vice President, Chief Business Officer -
Chris Ogden,
Interim Principal Accounting Officer and VP of Fin. & Accounting -
Leslie Robbins,
Sr. VP of Intellectual Property -
Alison Joly,
Sr. VP of Program & Alliance Management -
Danielle Olander,
Sr. VP, Talent & Systems Devel. -
Dr. Sridhar Viswanathan Ph.D.,
Sr. VP of Process Sciences & Manufacturing Operations -
Dr. Chau Cheng M.B.A., Ph.D.,
VP of Investor Relations & Corp. Communications -
Cynthia J Ladd,
Senior VP and General Counsel -
Marion Mc Court,
Director -
Rock Ventures Lp Third Rock...,
-
Neil Exter,
Director -
Rachel Humphrey,
Chief Medical Officer -
Ix L.P.Canaan Partners Ix L...,
-
Debanjan Ray,
Chief Financial Officer -
Hoyoung Huh,
Director -
Kevin P Starr,
10% owner -
Timothy M Shannon,
Director -
Ii Robert C. Goeltz,
Chief Financial Officer -
Zhen Su,
-
Robert I Tepper,
10% owner -
Partners L P/Ilbiotechnolog...,
-
Robin Knifsend,
Principal Accounting Officer -
James E Deerfield Mgmt L.P....,
-
Harbor Master Investors (Ca...,
10% owner -
Alan Ashworth,
-
Jeffrey B Landau,
Chief Business Officer -
Christopher Ogden,
Chief Financial Officer -
Marcia Belvin,
SVP, Chief Scientific Officer -
Yu Waye Chu,
Chief Medical Officer